Article

Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome

Department of Medicine, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico.
Puerto Rico health sciences journal (Impact Factor: 0.67). 07/2004; 23(2):89-93.
Source: PubMed

ABSTRACT

To compare effectiveness of oral therapy with reduced nicotinamide adenine dinucleotide (NADH) to conventional modalities of treatment in patients with chronic fatigue syndrome (CFS).
CFS is a potentially disabling condition of unknown etiology. Although its clinical presentation is associated to a myriad of symptoms, fatigue is a universal and essential finding for its diagnosis. No therapeutic regimen has proven effective for this condition.
A total of 31 patients fulfilling the Centers for Disease Control criteria for CFS, were randomly assigned to either NADH or nutritional supplements and psychological therapy for 24 months. A thorough medical history, physical examination and completion of a questionnaire on the severity of fatigue and other symptoms were performed each trimester of therapy. In addition, all of them underwent evaluation in terms of immunological parameters and viral antibody titers. Statistical analysis was applied to the demographic data, as well as to symptoms scores at baseline and at each trimester of therapy.
The twelve patients who received NADH had a dramatic and statistically significant reduction of the mean symptom score in the first trimester (p < 0.001). However, symptom scores in the subsequent trimesters of therapy were similar in both treatment groups. Elevated IgG and Ig E antibody levels were found in a significant number of patients.
Observed effectiveness of NADH over conventional treatment in the first trimester of the trial and the trend of improvement of that modality in the subsequent trimesters should be further assessed in a larger patient sample.

Full-text preview

Available from: upr.edu
  • Source
    • "Our results partially concur with these previous reports and suggest that the combination of CoQ 10 and NADH may improve max HR during an incremental cycle ergometer stress test. At present, few studies have been published that analyze the mechanisms by which CoQ 10 and NADH influence cardiovascular response [15] [16] [19] [20]. It has been suggested that these molecules may modulate the autonomic function by regulating the synthesis of endogenous catecholamines and acetylcholine [10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic Fatigue Syndrome (CFS) is a complex condition, characterized by severe disabling fatigue with no known cause, no established diagnostic tests, and no universally effective treatment. Several studies have proposed symptomatic treatment with coenzyme Q10 (CoQ10) and nicotinamide adenine dinucleotide (NADH) supplementation. The primary endpoint was to assess the effect of CoQ10 plus NADH supplementation on age-predicted maximum heart rate (max HR) during a cycle ergometer test. Secondary measures included fatigue, pain and sleep. A proof-of-concept, 8-week, randomized, controlled, double-blind trial was conducted in 80 CFS patients assigned to receive either CoQ10 plus NADH supplementation or matching placebo twice daily. Maximum HR was evaluated at baseline and at end of the run-in period using an exercise test. Fatigue, pain and sleep were evaluated at baseline, and then reassessed at 4- and 8-weeks through self-reported questionnaires. The CoQ10 plus NADH group showed a significant reduction in max HR during a cycle ergometer test at week 8 versus baseline (P = 0.022). Perception of fatigue also showed a decrease through all follow-up visits in active group versus placebo (P = 0.03). However, pain and sleep did not improve in the active group. Coenzyme Q10 plus NADH was generally safe and well tolerated. Our results suggest that CoQ10 plus NADH supplementation for 8 weeks is safe and potentially effective in reducing max HR during a cycle ergometer test and also on fatigue in CFS. Further additional larger controlled trials are needed to confirm these findings. Clinical trial registrationThis trial was registered at clinicaltrials.gov as NCT02063126. Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
    Full-text · Article · Jul 2015 · Clinical nutrition (Edinburgh, Scotland)
  • Source
    • "Twenty of the included trials adopted a two-arm parallel group design [10-12,14,15,17-27,29,30,33,35], three adopted a three-arm parallel group design [16,28,34], and one used a four-arm parallel group design [13], while two trials employed a cross-over design [31,32]. Nine trials adopted the CDC criteria for the diagnosis of CFS [11,20,22,24,25,27,28,31,32], five studies diagnosed CFS according to the criteria published by Fukuda [10,15,16,19,21], five used the Oxford criteria [12,17,18,30,35], two combined with Fukuda and Oxford criteria [13,23], and one used a different classification system [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Throughout the world, patients with chronic diseases/illnesses use complementary and alternative medicines (CAM). The use of CAM is also substantial among patients with diseases/illnesses of unknown aetiology. Chronic fatigue syndrome (CFS), also termed myalgic encephalomyelitis (ME), is no exception. Hence, a systematic review of randomised controlled trials of CAM treatments in patients with CFS/ME was undertaken to summarise the existing evidence from RCTs of CAM treatments in this patient population. Seventeen data sources were searched up to 13th August 2011. All randomised controlled trials (RCTs) of any type of CAM therapy used for treating CFS were included, with the exception of acupuncture and complex herbal medicines; studies were included regardless of blinding. Controlled clinical trials, uncontrolled observational studies, and case studies were excluded. A total of 26 RCTs, which included 3,273 participants, met our inclusion criteria. The CAM therapy from the RCTs included the following: mind-body medicine, distant healing, massage, tuina and tai chi, homeopathy, ginseng, and dietary supplementation. Studies of qigong, massage and tuina were demonstrated to have positive effects, whereas distant healing failed to do so. Compared with placebo, homeopathy also had insufficient evidence of symptom improvement in CFS. Seventeen studies tested supplements for CFS. Most of the supplements failed to show beneficial effects for CFS, with the exception of NADH and magnesium. The results of our systematic review provide limited evidence for the effectiveness of CAM therapy in relieving symptoms of CFS. However, we are not able to draw firm conclusions concerning CAM therapy for CFS due to the limited number of RCTs for each therapy, the small sample size of each study and the high risk of bias in these trials. Further rigorous RCTs that focus on promising CAM therapies are warranted.
    Full-text · Article · Oct 2011 · BMC Complementary and Alternative Medicine
  • Source
    • "Plant constituents that have been reported to be free radical scavengers and anti-lipoperoxidative include polyphenol (Maisuthisakul et al., 2007; Adedapo et al., 2009), reduced glutathione (Bhatia and Jain, 2004) and NADH (Stern et al., 2002). NADH therapy is known to have beneficial effects in patience with chronic fatigue syndrome (Santaella et al., 2004). Polyphenols have antioxidant and iron-chelating properties and can combat oxidative stress. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gunnera perpensa L. (Gunneraceae) is a medicinal plant used by Zulu traditional healers to induce labor, expel the placenta after birth and to relief menstrual pains. Phytochemical screening of the rhizomes revealed the presence of alkaloids, flavonoids, steroids, saponins, tannins and glycosides. Methanol extracts of G. perpensa exhibited strong scavenging of 2,2-Diphenyl-1-picryl-hydrazyl (DPPH) and 3-ethylbenzothiazoline-6-sulfonate (ABTS), but showed poor (< 50%) radical scavenging of nitric oxide, superoxide and hydroxyl radicals. At a concentration of 5 mg/100 ml, the extract was able to inhibit lipid peroxidation of the whole rat brain homogenate (71.13%) and lipoxygenase (30%) activity. The plant extract also contained reduced form of nicotinamide adenine dinucleotide (NADH, 3.8 m/g), total phenol (248.45 mg/g) and traces of sulfhydryl groups (SH). The total antioxidative capacity was 36% relative to ascorbic acid (AA) and 64% relative to butylated hydroxyl toluene (BHT). The cytotoxicity of the extract (LC 50) to brine shrimp larvae was 137.62 mg/ml. It is apparent that the antioxidant activity of G. perpensa contributes to its effectiveness in folk medicine.
    Full-text · Article · Dec 2010 · Journal of medicinal plant research
Show more